Consequently, it is important to consider that the predictive ability of sCD40L in STEMI may be diminished by antiplatelet medications, as these drugs inhibit platelet aggregation and the release of sCD40L.[12] hs-CRP exacerbates endothelial dysfunction and microvascular inflammation by activating the complement system, promoting monocyte chemotaxis, and enhancing oxidative stress. Here, CRP is linked to endothelial dysfunction.